Benjamin Graham Detailed Fundamental Analysis

Validea's guru fundamental report rates Regeneron Pharmaceuticals (REGN) at 71% using its Benjamin Graham-based 'Value Investor' model. While REGN, a large-cap growth stock, demonstrated strong fundamentals like long-term EPS growth and low debt, its valuation metrics (P/E and Price/Book ratios) failed the model's strict deep value criteria. This score places REGN below the 80% threshold for 'some interest' according to this methodology, despite its otherwise solid underlying fundamentals.

Analysis

Regeneron Pharmaceuticals (REGN) receives a 71% rating from Validea's Value Investor model, which is based on the deep value principles of Benjamin Graham. This score is notable as it falls below the 80% threshold that indicates strategic interest. The analysis reveals a dichotomy in the company's profile: REGN demonstrates strong underlying fundamentals, passing criteria for sales, current ratio, low long-term debt relative to net current assets, and solid long-term EPS growth. However, it fails on the two key valuation metrics central to the Graham strategy: the Price-to-Earnings (P/E) ratio and the Price-to-Book (P/B) ratio. This indicates that while the company is fundamentally sound, its current market valuation is too high to be considered a classic deep value opportunity according to this specific, rigorous methodology.

Key Decisions for Investors

• Deep value investors following a Graham-style approach should note that REGN fails on key valuation criteria, suggesting the stock is currently too expensive to meet their strict entry requirements.
• Investors with a growth-oriented or GARP (Growth at a Reasonable Price) strategy may find the strong fundamentals, particularly the positive long-term EPS growth and healthy balance sheet, to be compelling points that could justify the higher valuation.
• Consider monitoring REGN's valuation multiples; a significant price correction that brings the P/E and P/B ratios to more modest levels, without a degradation of its core financial health, could create a more attractive entry point for a wider range of investment styles.